These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1199 related articles for article (PubMed ID: 28593216)
1. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216 [TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up. Taipale H; Mehtälä J; Tanskanen A; Tiihonen J Schizophr Bull; 2018 Oct; 44(6):1381-1387. PubMed ID: 29272458 [TBL] [Abstract][Full Text] [Related]
3. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608 [TBL] [Abstract][Full Text] [Related]
4. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. Lähteenvuo M; Tanskanen A; Taipale H; Hoti F; Vattulainen P; Vieta E; Tiihonen J JAMA Psychiatry; 2018 Apr; 75(4):347-355. PubMed ID: 29490359 [TBL] [Abstract][Full Text] [Related]
5. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder. Hamina A; Taipale H; Lieslehto J; Lähteenvuo M; Tanskanen A; Mittendorfer-Rutz E; Tiihonen J JAMA Netw Open; 2024 Oct; 7(10):e2438358. PubMed ID: 39382894 [TBL] [Abstract][Full Text] [Related]
7. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Tiihonen J; Tanskanen A; Hoti F; Vattulainen P; Taipale H; Mehtälä J; Lähteenvuo M Lancet Psychiatry; 2017 Jul; 4(7):547-553. PubMed ID: 28578901 [TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of antipsychotic treatments in 1011 acutely hospitalized patients with schizophrenia: A one-year follow-up study. Hatta K; Katayama S; Ishizuka T; Sudo Y; Nakamura M; Hasegawa H; Imai A; Morikawa F; Shimada T; Misawa F; Ozaki S; Fujita K; Watanabe H; Nakamura H; Sugiyama N; Asian J Psychiatr; 2022 Jan; 67():102917. PubMed ID: 34875558 [TBL] [Abstract][Full Text] [Related]
10. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. McEvoy JP; Byerly M; Hamer RM; Dominik R; Swartz MS; Rosenheck RA; Ray N; Lamberti JS; Buckley PF; Wilkins TM; Stroup TS JAMA; 2014 May; 311(19):1978-87. PubMed ID: 24846035 [TBL] [Abstract][Full Text] [Related]
12. Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study. Joo SW; Kim H; Jo YT; Choi YJ; Ahn S; Lee J Psychol Med; 2023 Jan; 53(1):181-188. PubMed ID: 33855950 [TBL] [Abstract][Full Text] [Related]
13. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan. Chen W; Wu CS; Liu CC; Kuo PH; Chan HY; Lin YH; Chung YE; Chen WJ JAMA Netw Open; 2024 Jun; 7(6):e2417006. PubMed ID: 38884998 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Tiihonen J; Wahlbeck K; Lönnqvist J; Klaukka T; Ioannidis JP; Volavka J; Haukka J BMJ; 2006 Jul; 333(7561):224. PubMed ID: 16825203 [TBL] [Abstract][Full Text] [Related]
15. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Lafeuille MH; Grittner AM; Fortier J; Muser E; Fasteneau J; Duh MS; Lefebvre P Am J Health Syst Pharm; 2015 Mar; 72(5):378-89. PubMed ID: 25694413 [TBL] [Abstract][Full Text] [Related]
16. Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs. Weiser M; Davis JM; Brown CH; Slade EP; Fang LJ; Medoff DR; Buchanan RW; Levi L; Davidson M; Kreyenbuhl J Am J Psychiatry; 2021 Oct; 178(10):932-940. PubMed ID: 34256606 [TBL] [Abstract][Full Text] [Related]
17. Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study. Huang SS; Lin CH; Loh el-W; Yang HY; Chan CH; Lan TH Psychiatr Serv; 2013 Dec; 64(12):1259-62. PubMed ID: 24292730 [TBL] [Abstract][Full Text] [Related]
18. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338 [TBL] [Abstract][Full Text] [Related]
19. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367 [TBL] [Abstract][Full Text] [Related]
20. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. Taipale H; Tanskanen A; Luykx JJ; Solmi M; Leucht S; Correll CU; Tiihonen J Schizophr Bull; 2022 Jun; 48(4):774-784. PubMed ID: 35524479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]